Unknown

Dataset Information

0

CKAP2 (cytoskeleton-associated protein2) is a new prognostic marker in HER2-negative luminal type breast cancer.


ABSTRACT:

Background

Recently, we reported cytoskeleton-associated protein2 (CKAP2) as a possible new prognostic breast cancer marker. However, it has not yet been applied in clinic. Therefore, clinical significance of CKAP2 was evaluated in comparison with that of Ki-67 in a cohort of breast cancer patients, and the expression difference was analyzed in cell cycle-arrested cancer and fibroblast cells.

Methods

A total of 579 early breast cancer patients who underwent surgery at the National Cancer Center Hospital in Korea between 2001 and 2005 were accrued. CKAP2-positive cell count (CPCC) and Ki-67 labeling index (Ki-67LI) were evaluated by immunohistochemcal staining. The immunocytochemical staining patterns of CKAP2 and Ki-67 were analyzed in HeLa and human fibroblast cells after synchronization by double thymidine block.

Results

Although there was a significant correlation (R = 0.754, P < 0.001) between CPCC and Ki-67LI, only CPCC was correlated with DFS in overall population (HR, 2.029; 95% CI, 1.012-4.068; P = 0.046) and HER2-negative luminal subgroup (HR, 3.984; 95% CI, 1.350-11.762; P = 0.012) by multivariate analysis. In immunocytochemical staining, more than 50% of serum-starved or non-mitotic cell phase HeLa cells were positive for Ki-67, in comparison to the low CKAP2-positivity, which might explain the prognostic difference between CPCC and Ki-67LI.

Conclusions

The current study showed that CPCC but not Ki-67LI is an independent prognostic indicator in early breast cancer, more specifically in HER2-negative luminal breast cancer. The difference between two markers may be related to the lower background expression of CKAP2 in cancer cells.

SUBMITTER: Sim SH 

PROVIDER: S-EPMC5542386 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Recently, we reported cytoskeleton-associated protein2 (CKAP2) as a possible new prognostic breast cancer marker. However, it has not yet been applied in clinic. Therefore, clinical significance of CKAP2 was evaluated in comparison with that of Ki-67 in a cohort of breast cancer patients, and the expression difference was analyzed in cell cycle-arrested cancer and fibroblast cells.<h4>Methods</h4>A total of 579 early breast cancer patients who underwent surgery at the National  ...[more]

Similar Datasets

| S-EPMC4095689 | biostudies-literature
| S-EPMC5528705 | biostudies-literature
| S-EPMC9954084 | biostudies-literature
| S-EPMC7039866 | biostudies-literature
| S-EPMC4124146 | biostudies-literature
| S-EPMC3797106 | biostudies-literature
| S-EPMC10651910 | biostudies-literature
| S-EPMC5053632 | biostudies-other
| S-EPMC5297825 | biostudies-literature
| S-EPMC7299127 | biostudies-literature